VX-765 - Belnacasan

Based on 161 reference(s) in Google Scholar 8 10 161

Axon 3857

CAS [273404-37-8]

MF C24H33ClN4O6
MW 509.00

  • Purity: 99%
  • Optical purity: 99%
  • Soluble in DMSO



VX-765 is a novel Caspase-1 inhibitor being investigated for the treatment of epilepsy, currently being developed by Vertex. VX-765 is an orally-absorbed pro-drug of VRT-043198, a potent and selective inhibitor of ICE/caspase-1 sub-family caspases. VRT-043198 exhibits 100-10,000-fold selectivity against other caspase-3 and -6-9. In cultures of peripheral blood mononuclear cells and whole blood from healthy subjects stimulated with bacterial products, VRT-043198 inhibited the release of Interleukin (IL)-1beta and IL-18, but had little effect on the release of several other cytokines, including IL-1alpha, tumor necrosis factor-alpha, IL-6 and IL-8.

KEYWORDS: VX-765 | Supplier | Caspase-1 inhibitor | Belnacasan | VX765 | VX 765 | CT-VX765 | CAS [273404-37-8] | Amyloids | Caspase | Inhibitor | Enzymes | Prodrug

MB Boxer et al. A highly potent and selective caspase 1 inhibitor that utilizes a key 3-cyanopropanoic acid moiety. ChemMedChem. 2010 May 3;5(5):730-8.
Eda, Hiroyuki. Therapeutic potential for caspase inhibitors: Present and future. Design of Caspase Inhibitors as Potential Clinical Agents (2009), 251-287.
Caspase-1 inhibitor

Chemical name


Source information

Sold in collaboration with Chemietek

Parent CAS No.


The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...